NVS

Novartis
NYSE

Real-time Quotes | Nasdaq Last Sale

84.53
+0.39
+0.46%
Opening 14:25 10/22 EDT
OPEN
84.21
PREV CLOSE
84.14
HIGH
84.67
LOW
84.04
VOLUME
1.02M
TURNOVER
--
52 WEEK HIGH
99.84
52 WEEK LOW
69.18
MARKET CAP
193.49B
P/E (TTM)
26.95
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Novartis Received FDA Orphan Drug Designation for Branaplam (LMI070) in Huntington's Disease
Novartis (NYSE: NVS) today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation for branaplam (LMI070) in Huntington's disease (HD).
Benzinga · 1d ago
IPO Update: NLS Pharmaceutics Readies $20 Million IPO Plan
NLS Pharmaceutics has filed to raise $20 million in a U.S. IPO.The firm is advancing treatments for narcolepsy and ADHD.NLSP is thinly capitalized and has made no apparent progress on beginning trials for its lead candidate, so I'll pass on the IPO.
Seekingalpha · 1d ago
Is Amgen Stock A Buy With No Recent Updates On Its Dual Approach To Targeting Coronavirus?
Investor's Business Daily · 2d ago
The Zacks Analyst Blog Highlights: Novartis, Zoom Video, FIS, 3M and TOTAL
The Zacks Analyst Blog Highlights: Novartis, Zoom Video, FIS, 3M and TOTAL
Zacks · 3d ago
Top Research Reports for Novartis, Zoom Video & FIS
Top Research Reports for Novartis, Zoom Video & FIS
Zacks · 6d ago
Novartis Receives Positive CHMP Opinion For Leqvio
https://www.globenewswire.com/news-release/2020/10/16/2109800/0/en/Novartis-receives-positive-CHMP-opinion-for-Leqvio-inclisiran-a-potential-first-in-class-siRNA-for-the-treatment-of-high-cholesterol.html#:~:text=Basel%2
%2 · 6d ago
Opthea IPO: What Investors Should Know About The Genentech, Regeneron Challenger
Opthea, an Australian clinical stage biotech company, is going public to help fund its Phase 3 trials and take on two large biotech companies.
Benzinga · 6d ago
Novartis Pharmaceuticals Canada Announces Health Canada Has Approved Luxturna, A One-time Gene Therapy For Treatment Of Adult & Pediatric Patients With Vision Loss Due To Inherited Retinal Dystrophy
-Reuters
Reuters · 10/15 10:41
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NVS. Analyze the recent business situations of Novartis through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NVS stock price target is 104.50 with a high estimate of 105.00 and a low estimate of 104.00.
EPS
Institutional Holdings
Institutions: 1.43K
Institutional Holdings: 267.15M
% Owned: 11.67%
Shares Outstanding: 2.29B
TypeInstitutionsShares
Increased
327
8.61M
New
140
-1.60M
Decreased
358
18.30M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.11%
Pharmaceuticals & Medical Research
+0.26%
Key Executives
Non-Executive Chairman/Independent Director
Joerg Reinhardt
President/Chief Executive Officer
Chris Ilsley
Non-Executive Chairman
Alex Krauer
Non-Executive Chairman
Daniel Vasella
Chief Executive Officer/Executive Board
Vasant Narasimhan
Non-Executive Vice Chairman/Independent Director
Enrico Vanni
Corporate Executive/
Michael Ball
Chief Financial Officer/Executive Board
Harry Kirsch
Chief Human Resource Officer/Executive Board
Steven Baert
Chief Technology Officer/Executive Board
Steffen Lang
Chief Compliance Officer/Chief Risk Officer/Executive Board
Klaus Moosmayer
General Counsel/Executive Board
Shannon Klinger
Executive Board
Bertrand Bodson
Executive Board
James Bradner
Executive Board
Richard Saynor
Executive Board
Susanne Schaffert
Executive Board
John Tsai
Executive Board
Marie-France Tschudin
Executive Board
Robert Weltevreden
Secretary
Charlotte Pamer-Wieser
Director
Bridgette Heller
Director
Simon Moroney
Non-Executive Independent Director
Nancy Andrews
Non-Executive Independent Director
Ton Buechner
Non-Executive Independent Director
Patrice Bula
Non-Executive Independent Director
Srikant Datar
Non-Executive Independent Director
Elizabeth Doherty
Non-Executive Independent Director
Ann Fudge
Non-Executive Independent Director
Charles Sawyers
Non-Executive Independent Director
Frans van Houten
Non-Executive Independent Director
Andreas von Planta
Non-Executive Independent Director
William Winters
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
01/31/2020
Dividend USD 2.0067876
03/03/2020
--
Dividend USD 1.842184
03/04/2019
--
Dividend USD 1.909
03/06/2018
04/17/2017
Dividend USD 2.303
03/01/2017
04/11/2016
Dividend USD 1.766665
02/24/2016
04/14/2015
Dividend USD 2.259
03/02/2015
05/13/2014
Dividend USD 1.794
02/27/2014
04/01/2013
Dividend USD 2.057
02/26/2013
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About NVS
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines researches, develops, manufactures, distributes and sells patented prescription medicines to develop health outcomes for patients and healthcare providers. Sandoz develops, manufactures, distributes and sells prescription medicines, as well as pharmaceutical active substances that are not protected by valid and enforceable third-party patents. Alcon researches, develops, manufactures, distributes and sells eye care products. Alcon is a provider of eye care with product offerings in eye care devices and vision care. The Company's range of products includes pharmaceuticals and oncology medicines, generic and biosimilar medicines, and eye care devices.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Novartis AG (ADR) stock information, including NYSE:NVS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NVS stock methods without spending real money on the virtual paper trading platform.